|Atazanavir||HIV protease inhibitor|
|Cobicistat||Cytochrome P450 (CYP3A) inhibitor|
|AHFS/Drugs.com||Professional Drug Facts|
Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.
Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015. It was approved for medical use in the European Union in July 2015.
- "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
- "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
- "Evotaz EPAR". European Medicines Agency (EMA). Retrieved 25 May 2021.
- Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi:10.2147/HIV.S99063. PMC 4790521. PMID 27022304.
- "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.
- "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. "Summary Report" (PDF).
- "Atazanavir mixture with cobicistat". Drug Information Portal. U.S. National Library of Medicine.